Anti-PVRIG Antibodies for Selective Immune Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapies targeting costimulatory molecules face challenges in effectively activating cytotoxic T cells, NK cells, γδ T cells, and Th1 cells, and inhibiting the interaction of PVRIG and PVLR2, which are crucial for treating conditions like cancer and autoimmune diseases, while maintaining immune system functionality.

Innovation Solution

Development of anti-PVRIG antibodies with specific CDR sequences that activate cytotoxic T cells, NK cells, and γδ T cells, and inhibit the PVRIG-PVLR2 interaction, using antibodies such as CPA.7.001 to CPA.7.050 and CHA.7.502 to CHA.7.550, which compete for binding and modulate costimulatory signals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current immunotherapies target costimulatory molecules to activate immune cells, then immune response activation is improved, but the ability to effectively inhibit PVRIG-PVLR2 interaction and activate specific immune cell subsets is insufficient

Engineering Contradiction:

Improveimmune response activationVSAvoidability to activate specific immune cell subsets and inhibit PVRIG-PVLR2

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent develops anti-PVRIG antibodies with specifically engineered CDR sequences (CDR1, CDR2, CDR3) that change the binding parameters to achieve both activation of cytotoxic T cells, NK cells, γδ T cells, and Th1 cells, and inhibition of the PVRIG-PVLR2 interaction. This parameter change in antibody structure enables dual functionality that current immunotherapies lack.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If broad immune activation is achieved through costimulatory targeting, then overall immune response is enhanced, but selective activation of cytotoxic T cells, NK cells, γδ T cells, and Th1 cells remains challenging

Engineering Contradiction:

Improveoverall immune responseVSAvoidselective activation of specific immune cell subsets

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The anti-PVRIG antibodies exhibit local quality in their binding properties, where the engineered CDR sequences create specific binding characteristics that selectively activate certain immune cell subsets (cytotoxic T cells, NK cells, γδ T cells, Th1 cells) while maintaining broad immune response enhancement. This local specificity in antibody-antigen interaction achieves precise cell subset activation alongside overall immune enhancement.

Inventive Principle:

Principle #3Local quality

3Reliability

If PVRIG-PVLR2 interaction is inhibited to prevent tumor evasion, then tumor immune surveillance is improved, but maintaining immune system functionality while treating autoimmune diseases and cancer becomes complex

Engineering Contradiction:

Improvetumor immune surveillanceVSAvoidtherapeutic approach complexity for multiple conditions

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The anti-PVRIG antibodies demonstrate universality by serving multiple therapeutic functions simultaneously: they enhance tumor immune surveillance through PVRIG-PVLR2 inhibition, activate specific immune cell subsets for enhanced anti-tumor activity, and modulate costimulatory signals for potential treatment of autoimmune diseases and cancer. This multi-functionality reduces the need for separate therapies for different conditions.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250333503A1Anti-pvrig antibodies and methods of use

Publication Date: 2025.10.30 COMPUGEN

AI summary

The present invention is directed to anti-PVRIG antibodies and methods of using same.